Business Context and Reporting Period
This Form 8-K Current Report was filed by MEI Pharma, Inc. on April 7, 2014. The filing discloses the appointment of a new senior executive officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation details:
- Base Salary: $300,000 annually.
- Performance Bonus: Target of 30% of base salary, commencing in fiscal year 2015.
- Equity Grant: Option to purchase 120,000 shares of common stock.
- Exercise Price: Equal to the closing price of the stock on April 7, 2014.
Material Changes
On April 7, 2014, MEI Pharma, Inc. appointed David M. Urso as Senior Vice President of Corporate Development and General Counsel. Mr. Urso brings over two decades of life science industry experience, including roles as Chief Operating Officer and General Counsel at Tioga Pharmaceuticals and as a Principal at Forward Ventures.
Outlook, Risks, and Unusual Items
Compensation Structure and Termination Provisions:
- Vesting Schedule: 25% of options vest on April 7, 2015; the remaining 75% vest in equal monthly installments over 36 months.
- Change in Control: Options become fully vested upon a Change in Control.
- Termination Benefits: If terminated without Cause or if Mr. Urso resigns for Good Reason, he is entitled to a lump sum payment equal to nine months of base salary and accelerated vesting of options equivalent to nine additional months of service.
- Notice Period: Mr. Urso may terminate employment with one month's notice (unless for Good Reason, which requires specific notice timelines).
Risks: The filing notes no specific financial risks or contingencies beyond the standard terms of the employment agreement.
Investor Verification Checklist
- Verify the closing stock price on April 7, 2014, to determine the exercise price of the 120,000 option grant.
- Review the full text of the Employment Letter (Exhibit 10.1) for specific definitions of "Good Reason" and "Cause."
- Confirm the company's current cash position to assess the ability to fund the potential nine-month severance package if triggered.
- Check subsequent filings for any changes to the vesting schedule or equity plan.